Leave Your Message

Uhlolojikelele Oluphelele Lokwelashwa Kwe-Leukemia Eyi-Groundbreaking

I-CAR-T Therapy, emfushane ye-Chimeric Antigen Receptor T-Cell Immunotherapy, iyindlela yokwelapha ethuthukisiwe yofuzo ehlanganisa ukuguqula ufuzo amaseli T esiguli ukuze aqondise futhi abhubhise amangqamuzana omdlavuza. Ngokungafani nemithi yendabuko, ukwelashwa kwe-CAR-T kwenzelwe isiguli ngasinye futhi kudinga ukuqoqa ama-T cell egazini lesiguli ngaphambi kokuba abuyiselwe emzimbeni ngemva kobunjiniyela bofuzo.

    Izinkomba ze-CAR-T

    I-B-cell acute lymphoblastic leukemia

    I-myeloma eminingi

    I-Chronic lymphocytic leukemia

    I-Non-Hodgkin lymphoma

    Sabalalisa i-B-cell lymphoma enkulu

    I-SLE (Systemic Lupus Erythematosus)

    I-Myasthenia gravis

    Ezinye izifo ze-autoimmune

    Ukusebenza kahle komtholampilo kwe-CAR-T

    Izinkomba ze-CD19+20CAR-T:Iziguli ezine-B-cell non Hodgkin's lymphoma

    Isilinganiso se-CR senyanga eyodwa

    Isilinganiso se-PR senyanga eyodwa

    Inyanga eyodwa NOMA isilinganiso

    I-CRS≥3

    CRES≥3

    71.95% (59/82)

    25.6 (21/82)

    97.55 (80/82)

    12.19% (10/82)

    0

    Izinkomba ze-CD19+22CAR-T:Ukwelashwa kwe-CD19 ebuyele emuva kanye ne-refractory acute B-lymphocytic leukemia iziguli

    Isilinganiso se-CR senyanga eyodwa

    Isilinganiso se-PR senyanga eyodwa

    Inyanga eyodwa NOMA isilinganiso

    I-CRS≥3

    CRES≥3

    92.1% (35/38)

    7.9% (3/38)

    100% (38/38)

    15.79% (6/38)

    0

    Izinkomba ze-BCMACAR-T:Ukwelashwa kwe-myeloma eminingi ebuyele emuva kanye ne-refractory

    Isilinganiso se-CR senyanga eyodwa

    Isilinganiso se-PR senyanga eyodwa

    Inyanga eyodwa NOMA isilinganiso

    I-CRS≥3

    CRES≥3

    72.41% (21/29)

    27.59% (8/29)

    100% (29/29)

    6.9% (2/29)

    0

    UKUBUYEKEZWA KWE-CAR-T Therapy (2)tch

    Izinzuzo Zethu

     Ukwelashwa komuntu siqu: Ukwelashwa ngakunye kwe-CAR-T kwenziwa ngendlela oyifisayo esigulini, kuqinisekisa imiphumela yokwelashwa eqondiswe kakhulu nesebenza ngempumelelo.

     Izinketho Ezihlukahlukene Zokukhomba: Ngohlu olubanzi lwama-antigen aqondiwe, okuhlanganisa i-CD7, i-CD19, i-CD20, i-CD22, ne-BCMA, imikhiqizo yethu ye-CAR-T inikeza ukuguquguquka okungenakuqhathaniswa ekwelapheni izifo ezihlukahlukene ze-hematological kanye nezifo ezizimele.

     Impumelelo Yomtholampilo Efakazelwe: Izindlela zokwelapha zethu ze-CAR-T zibonise ukusebenza kahle okumangalisayo kuzo zonke izimo zomtholampilo eziningi, ngamanani ahlabayo okuxolelwa kanye namaphrofayili okuphepha, okuqinisa isikhundla sethu njengomholi ku-immunotherapy.

     High Izindleko-Ngempumelelo: Sinikeza umkhawulo wokuncintisana ngokwelashwa kwekhwalithi ephezulu ngamanani afinyeleleka kakhulu uma kuqhathaniswa neminye imikhiqizo ye-CAR-T emakethe.

     I-Cutting-Edge Technology: Ukusebenzisa intuthuko yakamuva kwezobunjiniyela bezakhi zofuzo, izindlela zokwelapha zethu ze-CAR-T zihlanganisa ikusasa lomdlavuza kanye nokwelashwa kwezifo ezizimele.

     Ukwesekwa Komtholampilo Ochwepheshe: Ithimba lethu labelaphi nabacwaningi abanolwazi olunzulu linikeza ukunakekelwa okuphelele kusukela ekubonisaneni kokuqala ngokusebenzisa ukuphathwa kokwelashwa kanye nokulandelela.

    Amaseli e-CAR-T manje aqashelwa kabanzi ngokusebenza kwawo ezigulini ezingazange zisabele ekwelashweni kwendabuko okufana nokwelashwa ngamakhemikhali noma ukufakelwa komnkantsha. Umphakathi wezokwelapha emhlabeni wonke uyawavuma amandla aphansi okwelashwa kwe-CAR-T ekuguquleni imiphumela yesiguli.

    incazelo2

    Fill out my online form.